Skip to Content
MilliporeSigma
All Photos(2)

Key Documents

1.50469

Supelco

Purospher® STAR RP-18 endcapped (3 µm)

L × I.D. 100 mm x 4.6 mm Hibar® RT HPLC column

Synonym(s):

Purospher® STAR RP-18 endcapped (3µm) Hibar® RT 100-4.6

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

UNSPSC Code:
41115709

material

stainless steel column

Quality Level

100

agency

suitable for USP L1

product line

Purospher®

feature

endcapped

packaging

1 ea of

extent of labeling

17% Carbon loading

parameter

400 bar pressure
65 °C max. temp.

technique(s)

HPLC: suitable
LC/MS: suitable
mass spectrometry (MS): suitable (High)

column L × I.D.

10 cm × 4.6 mm

surface area

330 m2/g

matrix

fully porous particle

matrix active group

C18 bonding phase

particle size

3 μm

pore size

120 Å pore size

operating pH range

1.5-10.5

separation technique

reversed phase
supercritical fluid (SFC)

storage temp.

no temp limit

Related Categories

General description

Purospher® STAR RP-18 endcapped, 3 µm HPLC columns are designed for universal use and allow the separation of basic, neutral, and metal chelating compounds with simple mobile phases and excellent peak symmetry. They are based on ultra-pure fully porous silica particles (Type B). These columns offer an outstanding stability from pH 1.5 to 10.5 over a wide temperature range, and suitability for up to 100% aqueous mobile phases. Plus, they demonstrate best all-round retention characteristics, as proven by the Tanaka test. Thanks to these features, Purospher® STAR RP-18 endcapped, 3 µm HPLC columns allow maximum flexibility to use the best chromatographic conditions for any separation including reversed phase.Purospher® STAR RP-18 endcapped, 3 µm Hibar® RT 150-4.6 is a ready to use stainless steel column suitable for connection to any HPLC system.The column dimension of 150 mm length x 4.6 mm I.D. is the optimal choice for high resolution HPLC separation of complex samples.The recommended guard column is Purospher® STAR RP-18 endcapped (5 µm) LiChroCART® 4-4 part number 1.50250.0001]. For direct connection to a Hibar® RT columns the Precolumn holder for 4-4 LiChroCART® cartridges, part number 1.51487.0001 can be used.Learn more about Purospher® STAR HPLC and UHPLC ColumnsLearn more about the Supelco HPLC Column portfolio and Method development:Brochure: HPLC and UHPLC Column Selection GuideBrochure: A Practical Guide to HPLC - Method Development Guide

Application

Intended to be used in the separation of aflatoxins, aldehydes, alkaloids, antibiotics, catecholamines, explosives, oligonucleotides, esters, fat soluble vitamins, lipids, fatty acids, flavonoids, ketones, nitrosamines, nucleosides, PAHs, PCBs, peptides, pesticides, phenols, phthalates, preservatives, steroids, metabolized steroids, sulfonamides, sweeteners, and water soluble vitamins.

Features and Benefits

  • Ultra-pure silica (99.999%) for excellent peak symmetry
  • High separation efficiency
  • Reproducible results from run-to-run and batch-to-batch
  • Best all-round performance according to Tanaka
  • Outstanding pH stability from pH 1.5 to 10.5
  • No phase collapse when using highly aqueous mobile phases
  • Good suitability for LC-MS applications

Analysis Note

Pressure: ≤ 130 bar
Theoretical Plates (N/m) (Anthracene): ≥ 120000
Symmetry (Anthracene): 0.8 - 1.4
Capacity factor (Anthracene): 4.0 - 6.0

Legal Information

Hibar is a registered trademark of Merck KGaA, Darmstadt, Germany
LICHROCART is a registered trademark of Merck KGaA, Darmstadt, Germany
Purospher is a registered trademark of Merck KGaA, Darmstadt, Germany

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Protocols

Identification, Assay and Organic Impurity Profiling Methods for Aripiprazole following the United States Pharmacopeia Monograph

Aripiprazole is an atypical antipsychotic and a partial dopamine agonist. It is primarily used in the treatment of schizophrenia, bipolar disorder, major depressive disorder, tic disorders, and irritability associated with autism. Aripiprazole was first approved by the U.S. Food and DrugAdministration in November 2002 for schizophrenia and by the European Medicines Agency in June 2004 for acute manic and mixed episodes associated with bipolar disorder.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service